Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease

E-ISSN： 1875-6190|14|3|238-249

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.14, Iss.3, 2016-04, pp. : 238-249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease

Current Pharmaceutical Design, Vol. 23, Iss. 33, 2018-01 ,pp. : 4936-4947

Bentham Science Publishers

Access to resources Recommend Favorite

The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson’s Disease Model

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 10, 2015-12 ,pp. : 1350-1366

Bentham Science Publishers

Access to resources Recommend Favorite

Entacapone in the management of Parkinson’s disease

By Waters Cheryl Henchcliffe Claire

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 957-963

Informa Healthcare

Access to resources Recommend Favorite

Dopaminergic substitution in Parkinson’s disease

By Müller Thomas

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 10, 2002-10 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Dopamine agonists in Parkinson’s disease

By Tintner Ron Jankovic Joseph

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite